Dihydroergotamine
- Generic Name
- Dihydroergotamine
- Brand Names
- Dhe-45, Migranal, Trudhesa
- Drug Type
- Small Molecule
- Chemical Formula
- C33H37N5O5
- CAS Number
- 511-12-6
- Unique Ingredient Identifier
- 436O5HM03C
- Background
A 9,10alpha-dihydro derivative of ergotamine. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile.
Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
- Indication
Dihydroergotamine (DHE) in all formulations is indicated for the acute treatment of migraine with or without aura in adults. As an injection, DHE is also indicated for the acute treatment of cluster headache episodes.
DHE is not indicated for migraine prevention or the management of hemiplegic or basilar migraine.
- Associated Conditions
- Cluster Headache, Migraine Headache, With or Without Aura
- Associated Therapies
- -
FDA turns down Satsuma’s nasal migraine treatment
FDA Accepts Satsuma and SNBL's Resubmitted NDA for STS101, a Nasal DHE Formulation for Migraine Treatment
Satsuma Pharmaceuticals and SNBL Announce Promising Results for Novel Nasal Powder Migraine Treatment
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.